ADDICTALGO: Study of the Characteristics of Chronic Pain in Patients With Addiction
Study Details
Study Description
Brief Summary
It is described in the literature a higher prevalence of pain in patients with an addiction but there are few studies describing the pain profile of patients with use disorder.
Pain has a very negative impact on the quality of life of opioid substituted patients. Improving knowledge on this point would make it possible to better guide specific care.
The investigator proposes to conduct a single-center descriptive observational study using questionnaires, without changing the management of patients with chronic pain.
The primary objective of the study is to determine the prevalence of chronic pain in patients with substance addiction hospitalized for addiction treatment.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
It is described in the literature a higher prevalence of pain in patients with an addiction but there are few studies describing the pain profile of patients with use disorder.
Pain has a very negative impact on the quality of life of opioid substituted patients. Improving knowledge on this point would make it possible to better guide specific care.
The investigator proposes to conduct a single-center descriptive observational study using questionnaires, without changing the management of patients with chronic pain. All patients admitted to hospitalization in the addictology department of the Lorient Hospital will be offered participation in the study.
The primary objective of the study is to determine the prevalence of chronic pain in patients with substance addiction hospitalized for addiction treatment.
The study will also evaluate the impact on daily activities of the presence of two chronic pathologies: chronic pain and addiction, describe the frequency of the two main psychiatric comorbidities of chronic pain: anxiety and depression, describe the different components of chronic pain in patients with substance addiction, and get information on analgesic medications.
Study Design
Outcome Measures
Primary Outcome Measures
- Prevalence of chronic pain in patients with substance addiction hospitalized for addiction treatment. [During the hospitalization, maximum 1 month]
Percentage of patients presenting with pain for more than three months among patients hospitalized in an addiction service for the management of an addiction
Secondary Outcome Measures
- Pain intensity in the last 24 hours [During the hospitalization, maximum 1 month]
Results of the Brief Pain Inventory : worst and least of pain in the last 24 hours
- Interference of pain on the quality of life [During the hospitalization, maximum 1 month]
Result of Brief pain inventory on general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life. On a scale from 0 (does not interfere) to 10 (completely interferes)
- Localisation of pain [During the hospitalization, maximum 1 month]
Drawing on a diagram of a human body
- Describe the frequency of the two main psychiatric comorbidities of chronic pain: anxiety [During the hospitalization, maximum 1 month]
Results of the anxiety scale of Hospital Anxiety and Depression scale. Positive if > 8. Minimum 0, maximum 21
- Describe the frequency of the two main psychiatric comorbidities of chronic pain: depression [During the hospitalization, maximum 1 month]
Results of the depression scale of Hospital Anxiety and Depression scale. Positive if > 8. Minimum 0, maximum 21
- Describe the prevalence of fibromyalgia among patients with substance addiction [During the hospitalization, maximum 1 month]
Results of the Fibromyalgia Rapid Screening Tool. Suspicion of fibromyalgia if >5 yes. Maximum 6 yes
- Information on analgesics medication [During the hospitalization, maximum 1 month]
Collection of current analgesic medication taken every day
- Describe the prevalence of neuropathic pain among patients with substance addiction [During the hospitalization, maximum 1 month]
Results of the DN3 (Douleur neuropathique 3). Suspicion of neuropathic pain when > 3/7
Eligibility Criteria
Criteria
Inclusion Criteria:
-
18 years old
-
Presence of addiction to at least one substance, based on DSM-5 criteria
-
Hospitalized in the addiction service of Lorient Hospital
-
Knowing how to read and write French
-
Not objecting to their participation in the study after informed information
Exclusion Criteria:
-
Already included during a precedent hospitalization
-
Adults subject to legal protection or deprived of their liberty.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Groupe Hospitalier Bretagne Sud | Lorient | France | 56100 |
Sponsors and Collaborators
- Groupe Hospitalier de Bretagne Sud
Investigators
- Principal Investigator: Alexandre Cauchie, MD, GH Bretagne Sud
Study Documents (Full-Text)
None provided.More Information
Publications
- Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006 May;10(4):287-333. doi: 10.1016/j.ejpain.2005.06.009. Epub 2005 Aug 10.
- Larson MJ, Paasche-Orlow M, Cheng DM, Lloyd-Travaglini C, Saitz R, Samet JH. Persistent pain is associated with substance use after detoxification: a prospective cohort analysis. Addiction. 2007 May;102(5):752-60. doi: 10.1111/j.1360-0443.2007.01759.x.
- Lusted A, Roerecke M, Goldner E, Rehm J, Fischer B. Prevalence of pain among nonmedical prescription opioid users in substance use treatment populations: systematic review and meta-analyses. Pain Physician. 2013 Nov-Dec;16(6):E671-84.
- Rosenblum A, Joseph H, Fong C, Kipnis S, Cleland C, Portenoy RK. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA. 2003 May 14;289(18):2370-8. doi: 10.1001/jama.289.18.2370.
- Voon P, Greer AM, Amlani A, Newman C, Burmeister C, Buxton JA. Pain as a risk factor for substance use: a qualitative study of people who use drugs in British Columbia, Canada. Harm Reduct J. 2018 Jul 5;15(1):35. doi: 10.1186/s12954-018-0241-y.
- 56LORC_2021_ADDICTALGO